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Abstract
Background: Current pediatric septic shock resuscitation guidelines from the American College of Critical Care
Medicine focus on the early and goal-directed administration of intravascular fluid followed by vasoactive
medication infusions for persistent and fluid-refractory shock. However, accumulating adult and pediatric data
suggest that excessive fluid administration is associated with worse patient outcomes and even increased risk
of death. The optimal amount of intravascular fluid required in early pediatric septic shock resuscitation prior to
the initiation of vasoactive support remains unanswered.
Methods/design: The SQUEEZE Pilot Trial is a pragmatic, two-arm, parallel-group, open-label, prospective pilot
randomized controlled trial. Participants are children aged 29 days to under 18 years with suspected or confirmed
septic shock and a need for ongoing resuscitation. Eligible participants are enrolled under an exception to consent
process and randomly assigned via concealed allocation to either the Usual Care (control) or Fluid Sparing
(intervention) resuscitation strategy. The primary objective of this pilot trial is to determine feasibility, based on the
ability to enroll participants and to adhere to the study protocol. The primary outcome measure by which success
will be determined is participant enrollment rate ("pass" defined as at least two participants/site/month, recognizing
that enrollment may be slower during the run-in phase). Secondary objectives include assessing (1) appropriateness
of eligibility criteria, and (2) completeness of clinical outcomes to inform the endpoints for the planned multisite
trial. To support the nested translational study, SQUEEZE-D, we will also evaluate the feasibility of describing
cell-free DNA (a procoagulant molecule with prognostic utility) in blood samples obtained from children enrolled
into the SQUEEZE Pilot Trial at baseline and at 24 h.
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Discussion: The optimal degree of fluid resuscitation and the timing of initiation of vasoactive support in order to
achieve recommended therapeutic targets in children with septic shock remains unanswered. No prospective study
to date has examined this important question for children in developed countries including Canada. Recruitment
for the SQUEEZE Pilot Trial opened on 6 January 2014. Findings will inform the feasibility of the planned
multicenter trial to answer our overall research question.
Trial registration: ClinicalTrials.gov Identifier NCT01973907, registered on 23 October 2013.
Keywords: Fluid therapy, Resuscitation, Shock, Sepsis, Pediatrics
Background
Rationale
Septic shock remains one of the most significant and
potentially preventable causes of death in children world-
wide, with pediatric mortality rates ranging from 15 to
70% [1, 2]. Current pediatric Surviving Sepsis Guidelines
[3, 4] from the American College of Critical Care Medi-
cine (ACCM) emphasize an early and goal-directed
approach to resuscitation [5–7]. These guidelines suggest
that fluid resuscitation should be aggressive with repeated
intravenously (IV) administered fluid boluses of 20 mL/
kg, such that some children may require as much as
200 mL/kg of fluid to achieve therapeutic endpoints [2].
The guidelines also recommend initiation of vasoactive
agents at the stage of “fluid-refractory shock,” i.e., when
there is persistent hypoperfusion despite at least 60 mL/kg
IV fluid [3]. While evidence suggests that adhering to
the resuscitation goals and guidelines of the ACCM
may improve mortality and functional morbidity [8, 9],
fluid resuscitation guidelines from the ACCM were de-
rived primarily from observational studies and expert
opinion [3].
Aggressive fluid administration in septic shock has re-
cently been called into question [10]. Accumulating adult
[11–14] and pediatric data [15–18] suggest that excessive
fluid resuscitation in patients with septic shock is associ-
ated with increased morbidity and mortality. This has
sparked a furious debate in both the adult and pediatric
medical literature on how “aggressive” fluid resuscitation
should be, given that the main morbidity and mortality in
septic shock is due not to refractory hypotension, but to
end-organ failure due in part to massive fluid overload
[19]. The overall objective of our research program is,
therefore, to evaluate whether a fluid-sparing strategy, that
involves earlier initiation and preferential escalation of
vasoactive medications to achieve ACCM goal-directed
targets, results in improved clinical outcomes for children
experiencing septic shock.
Relevant medical literature
Mortality in pediatric septic shock has significantly im-
proved since the introduction of rapid fluid resuscitation
in the first “golden” hour of resuscitation [6–9, 20].
Subsequent improvements in pediatric septic shock sur-
vival have been attributed to adherence to the first iter-
ation of the ACCM septic shock guidelines, and the use of
goal-directed targets [21, 22]. However, the largest and
most publicized pediatric trial of fluid resuscitation in
children with suspected septic shock (FEAST trial),
published in the New England Journal of Medicine in
2011, demonstrated an increased mortality among chil-
dren treated with aggressive fluid resuscitation in com-
parison to the conservative fluid resuscitation arm [15].
These results sparked a flurry of commentaries and at-
tempts to explain these unexpected findings [23–25].
The FEAST trial was conducted in sub-Saharan Africa,
and enrolled a significant proportion of children with
malaria. As a result, the pediatric critical care commu-
nity clearly acknowledges that these results, while im-
portant, are not necessarily generalizable to developed
countries such as Canada. These results did, however,
fuel further discussion and debate regarding the optimum
fluid resuscitation in the course of goal-directed therapy
in septic shock.
Emerging publications in the Intensive Care Unit (ICU)
medical literature suggest that excessive, compared to
conservative, fluid administration in adults with septic
shock worsens outcomes such as duration of mechan-
ical ventilation [17, 26], complications related to the
third-spacing of fluids [27, 28], length of ICU stay [17, 26],
and mortality [11–14]. Recent systematic reviews reveal a
paucity of randomized controlled trial (RCT) evidence,
other than the FEAST trial, examining the impact of fluid
resuscitation on mortality in children with septic shock
[29, 30]. This raises the important question of whether
children in developed countries would also benefit from
fluid-sparing resuscitation. A goal-directed fluid-sparing
strategy would, by default, require earlier initiation and
preferential escalation of vasoactive medications to target
ACCM hemodynamic goals [3]. There are potential ad-
verse effects attributable to the earlier initiation of vaso-
active medications that may outweigh those resulting
from an aggressive fluid administration strategy, providing
further justification for this study [27, 28, 31–33]. The op-
timal degree of fluid resuscitation and the timing of initi-
ation of vasoactive support in order to achieve therapeutic
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targets in children with septic shock remain unanswered.
No prospective study to date has examined this important
question for children in developed countries including
Canada.
Overall research question
In pediatric patients with septic shock, does a fluid-sparing
strategy to achieve ACCM therapeutic goals result in
improved clinical outcomes without an increased risk of
adverse events compared to the usual care of aggressive
fluid resuscitation, as currently recommended by the
ACCM guidelines?
Pilot trial primary research question
Is it feasible to conduct a multicentre trial using this
protocol?
Explanation for choice of comparators
There is currently not clinical equipoise to randomize
children with septic shock to a “No bolus” intervention.
For this reason, the only sensible way to test emerging
concepts while producing high-quality evidence is to in-
vestigate comparators of a “fluid-sparing” strategy versus
“usual care,” where the latter is fluid liberal.
Methods/design
The SQUEEZE Pilot Trial is a pragmatic two-arm,
parallel-group, open-label, prospective pilot RCT. We
will use this pilot RCT to determine the feasibility and
inform the appropriate methodological design of the
larger definitive trial [34, 35].
The primary objective of the SQUEEZE Pilot Trial is to
determine the feasibility of a large multicentre RCT to
answer our overall research question. Secondary objectives
are to assess the (1) appropriateness of the eligibility cri-
teria, and (2) completeness of clinical outcomes of interest
for the main study to inform the design of the full-scale
trial. Clinical outcomes under consideration for the defini-
tive trial include clinical endpoints related to:
1. Clinical course and procedures, e.g., Pediatric
Intensive Care Unit (PICU) admission rate, Length
of Stay, measures of organ dysfunction, i.e., PELOD-2
score, ventilator-free days, mortality, invasive lines and
procedures, laboratory and microbiological findings
2. Short-term hemodynamic outcomes, e.g., time to
shock-reversal, cardiovascular indices
3. Adverse events: (i) complications potentially
attributable to fluid overload, e.g., pulmonary
edema, pleural effusion requiring drainage,
abdominal compartment syndrome, and (ii)
complications potentially attributable to inotrope/
vasopressor use, e.g., signs of digital soft tissue
ischemia, need for revision amputation
The pilot trial primary and secondary study objectives
will be evaluated according to the outcomes listed in
Table 1. We will also collect additional data related to
study process, resource, and management aspects of
feasibility to inform conduct of the definitive multicentre
RCT. The proposed primary objective for the definitive
SQUEEZE Trial is to determine whether time to shock-
reversal is quicker in pediatric patients with septic shock
treated with a Fluid Sparing resuscitation strategy versus
Usual Care.
The SQUEEZE Pilot Trial includes a nested transla-
tional study, SQUEEZE-D. The overall objective of
SQUEEZE-D is to describe the levels of plasma cell-free
deoxyribonucleic acid (cfDNA) in pediatric septic shock.
cfDNA is released by activated neutrophils and is a potent
trigger of blood coagulation. In adult patients with severe
sepsis, cfDNA has high discriminative power to predict
ICU mortality [36]. The primary objective of SQUEEZE-D
in the context of the pilot trial is to evaluate the feasibility
of describing cfDNA in blood samples obtained for clinical
purposes at baseline and 24 h in children enrolled in
the SQUEEZE Pilot Trial. The secondary objectives of
SQUEEZE-D are to determine (1) the availability of the
required samples from patients enrolled in SQUEEZE
and (2) the process, resource, and management aspects
of feasibility which impact upon the ability to process
and test samples to inform the design of a larger-scale
study. The proposed primary objective of SQUEEZE-D
in the definitive trial is to determine the predictive
value of cfDNA on length of time in shock.
The detailed pilot trial protocol is organized in accord-
ance with the Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) guidelines, with
items corresponding to the SPIRIT 2013 checklist
(Additional file 1) [37, 38]. Required items, such as the
World Health Organization Trial Registration Data Set
(Additional file 2), a schedule of enrollment, interven-
tions, and assessments (Additional file 3), and a partici-
pant flow diagram (Fig. 1) are included here. The protocol
was registered at ClinicalTrials.gov (NCT01973907) prior
to enrollment of the first participant.
Setting
The SQUEEZE Pilot Trial currently includes McMaster
Children’s Hospital (Hamilton, Canada); however, we
will consider adding external Canadian site(s) once the
trial is established. Participating sites will be listed on
the ClinicalTrials.gov trial registration page.
Participants
Patients presenting to the emergency department, or
admitted to an inpatient ward (including the PICU) at
participating sites who meet the following eligibility
criteria:
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Inclusion criteria:
Inclusion criteria for 1 and 3 must be answered yes to
be eligible.
1. Age 29 days to under 18 years of age
*2aPersistent signs of shock defined as one or more of
the following:
(i) Vasoactive medication dependence (need for
vasoactive drug for hemodynamic support)
(ii)Hypotension (systolic blood pressure (SBP) and/or
mean blood pressure (MBP) below the 5th
percentile for age)
(iii)Abnormal perfusion, defined as the presence of two
or more of the following:
abnormal capillary refill (CR) (CR <1 s (flash) or CR
≥3 s (delayed)), tachycardia (heart rate (HR) above
the 95th percentile for age)
decreased level of consciousness
decreased urine output
*2bSuspected or confirmed septic shock
*2cFluid resuscitation threshold met. Patient has
received within the previous 6 h a minimum of:
(i) 40 mL/kg of isotonic crystalloid (0.9% normal saline
or Ringer’s lactate), and/or colloid (5% albumin) as
fluid bolus therapy administered IV for participants
<50 kg
or
(ii)δ2 L of isotonic crystalloid (0.9% normal saline or
Ringer’s lactate), and/or colloid (5% albumin) as IV
fluid bolus therapy for participants ≥50 kg
3. Fluid-refractory septic shock as defined by the
presence of 2a, 2b, and 2c.
*Adapted from the International Pediatric Sepsis
Consensus Conference: definitions for sepsis and
organ dysfunction in pediatrics [1]
δBased on the adult Surviving Sepsis Guidelines
initial targets for fluid resuscitation [4]
Exclusion criteria:
i) Patient admitted to the Neonatal Intensive Care
Unit (NICU)
ii) Full active resuscitative treatment is not within the
goals of care
iii)Shock secondary to causes other than sepsis
(i.e., obvious signs of cardiogenic shock, anaphylactic
shock, hemorrhagic shock, spinal shock)
Table 1 Summary of Pilot Trial outcomes
Pilot Trial outcomes Analysis Pass threshold
SQUEEZE
Primary outcomes
1. Participant enrollment ratea








2. Protocol adherence: ability to initiate study
procedures within 1 h of randomization
Simple proportion Not applicable
Secondary outcomes
1. Appropriateness of eligibility criteria as evidenced by the
ability to identify and enroll participants in a timely manner
Descriptive Not applicable
2. Completeness of the clinical outcomes of interest to inform
the design of the future multicenter trial
Descriptive Not applicable
3. We will also assess considerations related to study process,




1. The proportion of SQUEEZE participants for whom cell-free
deoxyribonucleic acid (cfDNA) can be described
Simple proportion Not applicable
Secondary outcomes
1. The availability of the required samples from patients enrolled
into SQUEEZE and
Simple proportion Not applicable
2. We will also assess considerations related to study process,
resource, and management aspects of feasibility which impact
upon the ability to process and test samples to inform the
design of a larger-scale study
Descriptive Not applicable
aRecognizing that enrollment may be slower during the initial run-in phase
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iv) Patients requiring resuscitation in the operating
room or Post-anesthetic Care Unit
v) Previous enrollment in this trial, where known by
the research team
Interventions
Patients will be randomized in a 1:1 ratio to either: (1)
Usual Care, or (2) Fluid Sparing.
For all participants, care providers will be provided with
a copy of the hemodynamic goals as specified in the
ACCM Surviving Sepsis Guidelines and instructed that
they should escalate treatment to achieve these targets
according to the assigned intervention. A copy of the
current ACCM Guidelines will also be provided to pro-
mote adherence to best practices in both study arms for
aspects of patient care not impacted by the study
intervention.
An illustration of the two study arms in ACCM
Guideline format is provided in Additional file 4, while
the ACCM Goal Directed Targets are summarized in
Additional file 5. Table 2 provides a detailed description
of the two-tiered study intervention. Each intervention
tier provides direction regarding the use of bolus fluid
therapy and vasoactive medications. A one-page flow
Fig. 1 Flow of participants
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diagram will be used in the clinical setting to provide
simple directions regarding implementation of the
intervention.
Criteria for discontinuing or modifying allocated inter-
ventions for a given trial participant:
We will allow for exit criteria from the study protocol
as follows:
i) Participant or their Substitute Decision Maker
(SDM) withdraws consent for ongoing study
participation
ii) Change in the medical goals of care for a study
participant, e.g., decision to limit escalation of
resuscitative therapies and/or withdrawal of life-
sustaining supportive measures
iii)Confirmatory evidence that the participant is
suffering from another form of shock other than
septic shock, e.g., occult hemorrhage
iv) The Most Responsible Physician (MRP) believes
that ongoing patient management according to
the assigned intervention will lead to patient
harm
Table 2 Detailed description of the SQUEEZE study arms
Intervention tier Usual Care arm Fluid Sparing arm
Tier 1 Usual Care Early initiation of vasoactive medications to spare fluid
Bolus fluid therapya,b • Following randomization, further isotonic fluid bolus
therapy [crystalloid (0.9% normal saline or Ringer’s lactate)
or colloid (5% albumin)] may be administered in any
volume and as requested by the caring physician
• Following randomization, further isotonic fluid bolus
therapy [crystalloid (0.9% normal saline or Ringer’s lactate)
or colloid (5% albumin)] should be avoided and provided
only if required due to: 1. delay in the ability to
immediately initiate vasoactive medication(s) and/or 2. to
treat intravascular hypovolemia. The reason/indication for
administration of further fluid bolus therapy prior to the
initiation of vasoactive medications must be documented
Vasoactive medicationc • The decision to initiate vasoactive medication(s) is at the
discretion of the treating physician. Vasoactive support
should not be started until the participant has received a
minimum of 60 mL/kg (3 L for participants ≥50 kg) of
isotonic fluid as boluses (includes fluid boluses received in
the 6 h prior to randomization)
• The choice of initial vasoactive medication and the initial
dose is to be at the discretion of the caring physician
• Vasoactive medication(s) should be initiated immediately
following randomization
• The choice of initial vasoactive medication and the initial
dose is to be at the discretion of the caring physician
Tier 2 Usual Care Preferential escalation of vasoactive medications
Bolus fluid therapya,b • Further isotonic fluid bolus therapy may be administered
at the discretion of the caring physician
• The type and dose of any further isotonic fluid bolus
therapy is at the discretion of the caring physician
• Further isotonic fluid bolus therapy may be administered
by the caring physician to treat documented inadequate
intravascular filling/preload
• If further isotonic fluid bolus therapy is provided, the dose
provided should be in 5–10-mL/kg aliquots (250-500 mL
for participants ≥50 kg) with the lowest acceptable volume
preferred and the indication for administration documented
• Aliquots of isotonic fluid bolus therapy may be
administered “back-to-back” if required to address
inadequate intravascular volume status
• The type of isotonic fluid bolus therapy provided is at the
discretion of the caring physician
Vasoactive medicationc • If initiated, vasoactive medication(s) may be titrated
(increased, decreased, or discontinued) at the
discretion of the caring physician
• Additional vasoactive medication(s) may be initiated at
the discretion of the caring physician
• Escalation of vasoactive medications should be the first line
to achieve hemodynamic goals (provided intravascular
volume status is judged to be adequate)
• The initiated vasoactive medication(s) may be titrated
(increased, decreased, or discontinued) at the discretion
of the caring physician
• Additional vasoactive medication(s) may be initiated at the
discretion of the caring physician
Intervention end • When the patient is free from vasoactive medication
support and shock is reversed or the patient is placed
on mechanical circulatory support,e.g., extracorporeal
membrane oxygenation (ECMO) or death occurs
• When the patient is free from vasoactive medication
support and shock is reversed or the patient is placed on
mechanical circulatory support, e.g., ECMO or death occurs
aBolus: a (fluid) bolus is a discrete volume of fluid prescribed to be administered intravascularly (intravenous (IV) or intraosseous (IO)) over a defined period of
time (ranging from stat, i.e., as fast as possible to typically no greater than 60 min). A fluid bolus typically ranges in size from usually not less than 5 mL/kg
(250 mL for participants ≥50 kg) to 20 mL/kg (1 L for participants ≥50 kg, although some clinicians may use per kilogram dosing in larger patients). A
documented medical order is required for a fluid bolus. Routine fluid replacement is not considered to be bolus(es)
bFluid therapy: isotonic crystalloid or colloid solutions which include 0.9% normal saline, Ringer’s lactate, and 5% albumin
cVasoactive medications are administered by intravascular (IV or IO) infusion and include: dobutamine, dopamine, epinephrine, norepinephrine, vasopressin,
phenylephrine, milrinone
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The site principal investigator (PI) or their delegate
should be contacted if any of these situations arise to
discuss the specific circumstances. If the PI withdraws a
participant from the study, clear and objective reason(s)
should be recorded.
Strategies to improve adherence to intervention protocols
For study participants, we will post an alert on the front of
the medical chart and inside their room, e.g., at the head
of the bed advising of trial enrollment and the assigned
intervention. In the Fluid Sparing arm, a fluid bolus record
requires the medical team to provide justification for any
fluid boluses administered to the participant. Data will be
reviewed in light of the assigned intervention and any
protocol deviations will be documented. Study process
feasibility includes protocol adherence [35]. We will
document and report the following protocol deviations:
failure to (1) implement study procedures within 1 h of
randomization, (2) prescribe fluid boluses in accordance
with protocol, (3) prescribe vasoactive medications in
accordance with protocol, and (4) provide notification of
enrollment to the participant or SDM per protocol. The
importance of protocol adherence will be routinely rein-
forced. There will be no restrictions with respect to con-
comitant care and interventions.
Study outcomes
Pilot trial outcomes are summarized in Table 1. The pro-
posed primary outcome for the full study is time to
shock-reversal. We have defined time to shock-reversal
as the amount of time (in hours) from allocation until
shock is reversed. Shock-reversal is defined based on the
ACCM therapeutic targets, when all of the following
criteria have been met:
1. Free from all vasoactive medication support
2. Normalization of HR (above the 5th, and below the
95th percentile for age)
3. Normalization of blood pressure (SBP and MBP
above the 5th percentile for age)
4. CR <3 s
Shock-reversal criteria will be assessed as documented
in the medical record. Shock will not be determined to
be reversed unless the patient has been free from vaso-
active infusions for 24 h. If a participant is placed on
mechanical circulatory support, such as extracorporeal
membrane oxygenation (ECMO), or if death occurs
during the intervention phase, shock will be coded as
“never reversed.”
Measurement of cfDNA (SQUEEZE-D)
The citrated plasma tube (CPT) used for determination
of the International Normalized Ratio (INR) and partial
thromboplastin time (PTT) is the same collection tube
used for cfDNA. We plan to use the CPT tube as the
source of plasma for cfDNA determination. The cfDNA
levels will be measured at baseline and at 24 h as previ-
ously described in the laboratory of Drs. Fox-Robichaud
and Liaw at the Thrombosis and Atherosclerosis Research
Institute [36].
Sample size
The target sample size for the SQUEEZE pilot, based on
the study objective of evaluating feasibility, is 50 subjects
(25 patients per arm). This is consistent with current
guidelines for sample size justification for pilot trials
[39]. We will consider adjusting the pilot trial sample
size upward to provide an opportunity for the new site(s)
to recruit sufficient subjects to allow for assessment of
external feasibility.
Screening and recruitment
Patients will be screened for eligibility from the follow-
ing patient care areas: emergency department, medical
and surgical wards, and the Pediatric Critical Care Unit
(PCCU). Posters and information sessions will be used
to promote the study to physician and nursing staff,
and trainees. The research coordinator and/or PI will
be paged for any potentially eligible patient, e.g., sus-
pected sepsis, receiving a fluid bolus. If/when a patient
is screened and determined to meet study eligibility
criteria, and provided there is no objection by the MRP
or their delegate, the randomization procedures will be
executed immediately and the patient enrolled. This
trial will use an exception to consent (deferred consent)
process (see “Ethical Considerations”).
Allocation sequence generation, allocation concealment,
participant enrollment, and communication of participant
assignment
The allocation sequence will be created by the Biostatis-
tics Unit and this information will be kept secret from,
and inaccessible by, the investigators. The allocation se-
quence will be computer-generated and utilize simple
randomization, with no stratification or blocking. The al-
location sequence will be implemented through a third
party computer-based process accessible via telephone
on a 24-h basis. A research assistant or one of the site
investigators will enroll eligible participants into the
study and be responsible for communicating the
assigned intervention.
Blinding
The investigators, research staff, and treating health care
providers will all be blinded to the allocation sequence.
It will not be possible to blind the investigators, treating
physicians, or bedside nursing staff from participant
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assignment as these individuals will need to be aware of,
and implement, the intervention. We will evaluate the
feasibility of blinding the research assistants (who will
obtain Ultrasonic Cardiac Output Monitor (USCOM™)
measurements) to participant treatment assignment. The
data analysts will be blinded to treatment assignment
through use of a numeric code in the trial database.
Activities to promote participant retention and follow-up
We do not anticipate difficulties with participant
follow-up given that those enrolled will be receiving
close monitoring and management for suspected septic
shock. Data collected prior to approaching participants/
SDMs for written consent to continue study participation
will be retained for all participants enrolled in the trial.
Where a protocol deviation occurs, this information in-
cluding the reason will be noted and data collection will
otherwise continue according to protocol.
Data collection methods
Participant demographic data and SQUEEZE outcome
data will be collected from the hospital chart by a research
assistant or one of the investigators, trained in use of the
Data Collection Forms. The investigators and research as-
sistants will be trained in the use of the noninvasive
USCOM™ ultrasound device for study purposes at sites
where this technology is available. At the times specified
within the study protocol, and where feasible, USCOM™
measurements will be obtained by one of these individuals
and recorded on the related Data Collection Form. Dr.
Fox-Robichaud will be responsible for oversight of
SQUEEZE-D outcome data collection.
Data collection, management, and security
Trial data will be collected by trained research staff or
one of the study investigators according to study proce-
dures. Data will be recorded on a paper-based Data Col-
lection Form and then entered into the electronic
REDCap Case Report Form (CRF) by trained research
staff [40]. Paper files will be kept locked and secure in
accordance with local laws and regulations. SQUEEZE-D
outcome data will be stored in the Team Sepsis database,
which is located at the Thrombosis and Atherosclerosis
Research Institute (TaARI).
Statistical methods for analyzing primary and secondary
outcomes
Baseline characteristics and outcome variables (both pri-
mary and secondary) will be summarized using descriptive
summary measures. Data analysis will consist of calculating
simple proportions for the feasibility outcomes. Analysis of
feasibility outcomes will be descriptive expressed as an
estimate with 95% confidence interval. Clinical outcomes
(blinded) will be estimated for the purposes of estimating
the sample size calculations for the planned definitive trial.
Analysis and reporting of the results with follow the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines for reporting RCTs [41, 42]. Because we plan to
include (roll-in) the pilot trial participants in the definitive
trial, we do not plan to perform analyses of clinical
outcomes. All analyses will be performed using SAS 9.2
(Cary, NC, USA).
Data Safety and Monitoring Board
Normally a Data Safety and Monitoring Board (DSMB)
is required for studies involving vulnerable populations
including children. However, we decided not to set up a
DSMB for this pilot trial given the minimal risk attribut-
able to participation. Further, the study duration is too
short for the DSMB process [43].
Steering Committee
The Steering Committee will consist of Drs. Parker,
Choong, Thabane, and Fox-Robichaud and will oversee
the execution and conduct of the study. The PI and the
Steering Committee will monitor adverse events (AEs),
and report all serious adverse events (SAEs) to the
Research Ethics Board (REB).
Interim analyses, stopping rules, auditing
As this is a pilot trial, there will be no interim analysis and
no predetermined stopping rules. There are no planned
audits. Our study may be subjected to audit by the REB(s)
of participating sites. As a clinical trial, our study may also
be subjected to audit by Health Canada.
Harms
The number and type of SAEs that occur will be moni-
tored by the trial Steering Committee. There are many
published complications that can normally occur as a re-
sult of septic shock and/or its treatment including multior-
gan dysfunction and death. The vast majority of children
in North America now survive septic shock; they may fully
recover or they may be left with residual/permanent dis-
ability. The decision as to whether an AE is a SAE will be
at the discretion of the PI based on proposed guiding prin-
ciples for academic critical care research [44]. All SAEs
along with the Steering Committee’s interpretation of attri-
bution, will be reported to the REB. Data regarding SAEs
will be collected and reported.
Research Ethics Board approval and communication of
protocol modifications
Approval to conduct this pilot trial has been granted by
the Hamilton Integrated Research Ethics Board (Project
# 13-295). Each participating site must seek and receive
full REB approval for trial participation prior to enrolling
any participants.
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Any modifications to trial procedures must be communi-
cated to, reviewed by, and approved by the Hamilton Inte-
grated REB, as well as the REBs of any other participating
sites. The PI will be responsible for communicating
approved changes in the trial protocol to the research
coordinator.
Consent and assent procedures
Pediatric septic shock is a recognized medical emergency
and, given that our study will evaluate a time-sensitive re-
suscitation protocol, we will use an exception to consent
process (deferred consent) to achieve timely enrollment,
randomization, and initiation of study procedures. The
use of an exception to consent process for research evalu-
ating treatment of emergency conditions has precedent
[45–47] and is supported in Canada by the Tri-Council
Policy Statement: Ethical Conduct for Research Involving
Humans (TCPS2) (Chapter 3, Article 3.8) [48]. The use of
an exception to consent process to conduct this study is
ethical because some research cannot be conducted with-
out the use of alternate consent models [48].
The participant and/or the SDM for the participant (for
children who are incapable of consent) will be notified
that they have been enrolled into a trial. At the earliest ap-
propriate opportunity, the research coordinator or one of
the study investigators will approach the participant or
SDM to provide detailed information about the study and
seek consent for ongoing participation. It will be made
clear that ongoing study participation is voluntary and
that any decision regarding further participation will not
influence the medical care provided. Participants who are
incapable of providing consent will be approached for
assent as applicable. We will also monitor participants on
an ongoing basis for signs of dissent.
Plans for collection and use of personal health
information
Collection of participant identifiers will be limited to those
determined to be necessary for trial purposes. Participants
will be assigned a unique identifying code number, with
participant identifiers kept separate from other trial data
collected. The file linking participant code numbers to
identifying information will be maintained on a password-
protected computer while paper CRFs will be kept locked
within a filing cabinet in a secure area.
Endpoint adjudication
We will adjudicate the time of resolution of septic shock,
according to our study definitions, and post-randomization
exclusions, e.g., patients for whom it is subsequently deter-
mined that shock was clearly due to another cause.
Data Management Team
The Data Management Team includes the investigators,
the research coordinator, and the REDCap super admin-
istrator. The REDCap super administrator controls the
setup of projects and, together with the PI, establishes
user accounts and user rights for the research team.
Authorship eligibility
Criteria for authorship on any manuscript disseminating
study results will be determined in accordance with the
statement from the International Committee of Medical
Journal Editors [49]. Medical/professional writers will not
be involved in manuscript preparation.
Plans for communication of trial results and data access
Plans for communication of trial results include presen-
tation at one or more national or international scientific
meetings and publication in a peer-reviewed journal.
The investigators plan to eventually make the final trial
data set publicly available.
Discussion
We describe a pragmatic pilot RCT evaluating a fluid-
sparing intervention in pediatric septic shock. Fluid resus-
citation is a hot topic in need of rigorous study to inform
optimal patient care. Our research aims to fill this gap
with high-quality evidence. Resuscitation trials face unique
challenges, given that interventions are frequently time-
sensitive in vulnerable patients. This is certainly true of
our study and supports the need for an initial pilot trial to
evaluate feasibility prior to proceeding with a larger study.
Pilot trials also offer an opportunity to test and refine trial
processes and procedures before embarking on a more
costly and complex endeavor.
Making our trial pragmatic was a priority to best re-
flect how the intervention would work in day-to-day
practice. For this reason the trial contains very few ex-
clusion criteria and, apart from these, aims to enroll all
children with persistent signs of shock in the setting of
suspected or proven infection. We recognize and accept
that “usual care” for some study participants, such as
those with premorbid cardiac conditions or renal
impairment, may approach that of the intervention
strategy. However, randomization should lead to these
and other patients with analogous circumstances being
evenly distributed between the study arms in any large-
scale trial. Also pragmatic, we suggest that clinicians
follow the ACCM guidelines for treatments apart from
those impacted by the study intervention; however, we do
not rigidly require guideline adherence. Some elements of
the Surviving Sepsis Guidelines are currently under
debate as a result of recent high-profile publications
while others are in the process of being studied. Of
particular note, the PROCESS, ARISE, and PROMISE
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trials challenge (in adults) the utility of aggressive treat-
ment to meet ACCM goals such as central venous pres-
sure (CVP) and hemoglobin targets [50–52]. However,
we do not consider these recent publications a threat to
our investigation. Rather, evidence supporting a move
away from aggressively targeting measures, such as
CVP, actually supports adherence to our fluid-sparing
intervention. Changing attitudes towards other targets,
such as transfusion thresholds, should also be evenly
distributed between groups as is expected for both
known and unknown confounders.
A number of considerations went into defining the
study intervention. Without doubt a large volume of
fluid may be administered in the initial stages of septic
shock resuscitation prior to the initiation of vasoactive
support. Early initiation of vasoactive support was the
only acceptable way to mitigate this, with permissive
hypotension the alternative. In children, hypotension is a
late clinical finding and we expect that inaction in the
face of hypotension would be unacceptable to any
clinicians providing care for children with septic shock
(including our team). An important caveat, however, is
that physiologically adequate end-organ perfusion and
age-based blood pressure targets are not necessarily one
in the same. Nonetheless, the ACCM currently defines
goal-directed hemodynamic targets by age – at least
during the early stages of resuscitation (Additional file 5)
[3, 4]. While the early initiation of vasoactive medica-
tions could define the intervention alone, we felt that
this was likely insufficient to result in meaningful fluid
sparing among any participants but those with the
mildest cases of septic shock. To be effective, a fluid-
sparing intervention likely requires an ongoing strategy
to limit fluid administration after vasoactive support has
been initiated.
We also sought to define our control arm pragmatic-
ally while being mindful of the need to achieve between-
group separation. Consistent with the ACCM guidelines,
we request that vasoactive support not be initiated in
participants randomized to the Usual Care arm until at
least 60 mL/kg (3 L for patients >50 kg) of isotonic fluid
boluses has been administered from the time of shock
onset. We expect between-group separation to be poten-
tially challenging to evaluate, given the small pilot trial
sample size and resulting increased risk of imbalance in
potentially important confounders such as illness sever-
ity. Depending on the nature of these findings, further
modifications to the study inclusion criteria and/or the
intervention may be required.
The planned primary outcome for the definitive trial is
time to shock-reversal. We consider time to shock-
reversal a clinically meaningful outcome since this meas-
ure is objective and impacts the need for critical care re-
sources. While we will measure and report PICU Length
of Stay, this outcome may be influenced by a host of fac-
tors apart from the patient’s condition, rendering it less
useful. Another candidate primary outcome is organ
dysfunction, as measured by PELOD-2 [53]. While we
will report mortality data, mortality is not an appropriate
or feasible primary outcome for many pediatric trials
due to high survivorship in children compared to adults
for many conditions and a comparatively smaller num-
ber of available participants.
We expect that one of the most contentious aspects of
this study will be our use of an exception to consent
process. Considering the rapid rate at which septic shock
resuscitation unfolds, as well as the life-threatening
emergency nature of the situation, it is impracticable to
seek prospective informed consent and any attempt to do
so would risk coercion. Early enrollment in the course of
resuscitation is also required from a scientific perspective
to achieve a meaningful impact of the intervention. We
are genuinely interested in SDM experiences with the
exception to consent process and research is also under-
way to evaluate this specifically [54].
The optimal degree of fluid resuscitation and the timing
of initiation of vasoactive support in order to achieve
therapeutic targets in children with septic shock remain
unanswered. In their systematic review Ford et al. con-
cluded “The most important direction for future research
is the applicability of the findings of the FEAST trial to
other populations and settings” [16]. SQUEEZE will help
to answer this very question in children with access to
advanced critical care in countries such as Canada. The
pilot trial described herein represents the first step in
achieving this aim.
Trial status
Active recruitment at the time of manuscript submis-
sion. Recruitment is now closed.
Additional files
Additional file 1: Title of data: SPIRIT 2013 checklist. Description of data:
completed SPIRIT 2013 checklist: recommended items to address in a
clinical trial protocol and related documents. (PDF 108 kb)
Additional file 2: Title of data: items from the World Health
Organization Trial Registration Data Set. Description of data: items from
the World Health Organization Trial Registration Data Set. (PDF 110 kb)
Additional file 3: Title of data: schedule of enrollment, interventions,
and assessments. Description of data: schedule of enrollment,
interventions, and assessments. (PDF 155 kb)
Additional file 4: Title of data: SQUEEZE study algorithm as Illustrated in
ACCM Guideline Format. Description of data: SQUEEZE study algorithm as
Illustrated in ACCM Guideline Format. (PDF 1162 kb)
Additional file 5: Title of data: ACCM Goal Directed Targets from the
Surviving Sepsis Guidelines. Description of data: summary of ACCM
Goal Directed Targets from the Surviving Sepsis Guidelines [3, 4].
(PDF 78 kb)
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